STOCK TITAN
  1. Home
  2. Sec-filings
  3. CORT
  4. [Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity

Corcept exec sells 58K shares after option exercise

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

CORCEPT THERAPEUTICS INC (CORT) reported that President, Oncology Roberto Wandenkolk Vieira exercised stock options for 58,333 shares of common stock at $21.63 per share on September 2, 2026, then sold 58,333 shares in multiple open-market transactions and had 102 shares withheld to satisfy tax obligations. These sales were made under a Rule 10b5-1 trading plan adopted on June 17, 2026. On September 1, 2026 he also acquired 138 shares through a purchase plan and 138 restricted shares that vest after one year.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Vieira Roberto Wandenkolk
Role President, Oncology
Sold 58,333 shs ($6.46M)
Approx. gross sale proceeds $6.46M
Approx. exercise cost $1.26M
Approx. pre-tax spread $5.20M
Type Security Shares Price Value
Exercise Stock option (right to buy) F16 58,333 $0.00 $0.00
Tax Withholding Common Stock F5, F6, F7 102 $113.38 $12K
Exercise Common Stock F7 58,333 $21.63 $1.26M
Sale Common Stock F8, F9, F7 23,600 $109.3506 $2.58M
Sale Common Stock F8, F10, F7 23,770 $110.7004 $2.63M
Sale Common Stock F8, F11, F7 1,537 $111.3733 $171K
Sale Common Stock F8, F12, F7 974 $112.3966 $109K
Sale Common Stock F8, F13, F7 1,606 $113.7187 $183K
Sale Common Stock F8, F14, F7 5,621 $114.5779 $644K
Sale Common Stock F8, F15, F7 1,225 $115.4395 $141K
Grant/Award Common Stock F1, F2, F3 138 $113.38 $16K
Grant/Award Common Stock F4, F3 138 $0.00 $0.00
Holdings After Transaction: Stock option (right to buy) — 141,667 contracts (Direct); Common Stock — 4,242 shares (Direct)
Footnotes (16)
  1. F1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
  2. F2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
  3. F3. Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  4. F4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
  5. F5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
  6. F6. The closing price on September 1, 2026 was used to calculate the withholding obligation.
  7. F7. Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  8. F8. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
  9. F9. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $108.97 to $109.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  10. F10. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.06 to $111.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  11. F11. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.06 to $111.945 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  12. F12. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.08 to $113.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  13. F13. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.11 to $114.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  14. F14. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.24 to $115.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  15. F15. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.255 to $115.57 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  16. F16. Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.
Options exercised 58,333 shares Stock options exercised for common stock on September 2, 2026
Option exercise price $21.63 per share Exercise price of stock option converted into 58,333 common shares
Shares sold 58,333 shares Total common shares sold in multiple open-market transactions on September 2, 2026
Sale price range (weighted averages) $109.35–$115.44 per share Weighted average prices across reported sale tranches
Tax withholding shares 102 shares at $113.38 per share Shares withheld to satisfy tax obligations on RSU vesting
Purchase plan acquisition 138 shares at $113.38 per share Shares bought under the 2024 Incentive Award Plan on September 1, 2026
Restricted stock award 138 shares Unvested restricted shares granted September 1, 2026, vesting 100% after one year
Stock option expiration February 1, 2034 Expiration date of the exercised stock option
Rule 10b5-1 plan regulatory
"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
restricted stock awards financial
"Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
weighted average sale price financial
"Represents the weighted average sale price for the entire number of shares sold"
tax withholding obligations financial
"shares were withheld by the Issuer in order to satisfy certain tax withholding obligations"
Incentive Award Plan financial
"purchase plan established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan"
An incentive award plan is a formal program that rewards employees, executives, or directors with cash, stock, options, or other pay when the company meets set goals or performance targets. Like a sales commission or a loyalty program that pays out when you hit milestones, it’s designed to align staff behavior with company objectives; investors care because it affects a company’s costs, share count (dilution), leadership incentives, and long-term value creation.

FAQ

What did Corcept Therapeutics (CORT) executive Roberto Vieira do in this Form 4?
He exercised options for 58,333 shares of Corcept common stock at $21.63 per share on September 2, 2026, then sold 58,333 shares in multiple open-market trades and had 102 shares withheld to cover tax obligations.

Were the Corcept Therapeutics (CORT) insider sales made under a Rule 10b5-1 plan?
Yes. The filing states the sales were made pursuant to a Rule 10b5-1 plan adopted by Roberto Vieira on June 17, 2026, which was in effect at the time of the September 2, 2026 transactions.

How many Corcept Therapeutics (CORT) shares did the insider sell and at what prices?
On September 2, 2026, Roberto Vieira sold a total of 58,333 shares of common stock in several trades at weighted average prices ranging from about $109.35 to $115.44 per share, with detailed price ranges disclosed in the footnotes.

What option exercise did the Corcept Therapeutics (CORT) executive report?
He reported exercising a stock option for 58,333 shares of Corcept common stock at an exercise price of $21.63 per share. The option, expiring February 1, 2034, vests monthly after an initial 25% vesting on January 29, 2025.

What shares were withheld for taxes in this Corcept Therapeutics (CORT) Form 4?
The issuer withheld 102 shares of common stock at a price of $113.38 per share on September 2, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units.

What additional share awards did Roberto Vieira receive from Corcept Therapeutics (CORT)?
On September 1, 2026, he acquired 138 shares through a purchase plan at $113.38 per share and received 138 shares underlying unvested restricted stock awards that will vest 100% on the one-year anniversary if specified conditions are met.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Vieira Roberto Wandenkolk
(Last)(First)(Middle)
C/O CORCEPT THERAPEUTICS INCORPORATED
101 REDWOOD SHORES PARKWAY
(Street)
REDWOOD CITY CALIFORNIA 94065
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President, Oncology
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/01/2026A138(1)A$113.38(2)4,206(3)D
Common Stock09/01/2026A138(4)A$0.004,344(3)D
Common Stock09/02/2026F(5)102D$113.38(6)4,242(7)D
Common Stock09/02/2026M58,333A$21.6362,575(7)D
Common Stock09/02/2026S(8)23,600D$109.3506(9)38,975(7)D
Common Stock09/02/2026S(8)23,770D$110.7004(10)15,205(7)D
Common Stock09/02/2026S(8)1,537D$111.3733(11)13,668(7)D
Common Stock09/02/2026S(8)974D$112.3966(12)12,694(7)D
Common Stock09/02/2026S(8)1,606D$113.7187(13)11,088(7)D
Common Stock09/02/2026S(8)5,621D$114.5779(14)5,467(7)D
Common Stock09/02/2026S(8)1,225D$115.4395(15)4,242(7)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy)$21.6309/02/2026M58,333 (16)02/01/2034Common Stock58,333$0.00141,667D
Explanation of Responses:
1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
3. Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
6. The closing price on September 1, 2026 was used to calculate the withholding obligation.
7. Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
8. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
9. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $108.97 to $109.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
10. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.06 to $111.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
11. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.06 to $111.945 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
12. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.08 to $113.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
13. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.11 to $114.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
14. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.24 to $115.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
15. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.255 to $115.57 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
16. Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.
Remarks:
The power of attorney under which this form was signed is on file with the Commission.
/s/ Joseph Douglas Lyon, as attorney-in-fact for Roberto Wandenkolk Vieira09/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on CORT

Trending in the feed

Open the live feed